Breakthrough Cancer Treatment for Dogs: Akadeum's Innovative T Cell Technology Shows Promise
In a groundbreaking development for veterinary medicine, Akadeum Life Sciences recently announced the successful application of their Human T Cell Leukopak Isolation Kit in the treatment of canine cancer. This innovative approach has been put to the test by LEAH Labs in collaboration with veterinary oncologist Dr. Jeffrey Bryan from the University of Missouri.
Two dogs, named Lou and Sadie, were the first to receive this pioneering treatment. Lou, a 10-year-old Beagle, and Sadie, an 8-year-old Collie/Pyrenees mix, were both diagnosed with advanced stages of a severe form of canine lymphoma, known as metastatic multicentric diffuse large B cell lymphoma. Traditionally, this diagnosis carries a grim prognosis; however, the newly adopted CAR-T cell therapy, utilizing genetically engineered human T cells isolated through Akadeum's technology, has resulted in a stunning turnaround.
After receiving the infusion of the CAR-T cells, both dogs experienced complete clinical remission within a remarkably short period, making history as the first patients ever to undergo such treatment with CAR-T cells in a veterinary setting. Throughout a three-week observational study, consistent measurements illustrated a significant decrease in tumor size across various sites, confirmed by X-ray and ultrasound imaging. Furthermore, the process utilized advanced PET imaging technology that allowed visualization of the CAR T cells in their injected lymph nodes.
This innovative technology employed by Akadeum relies on a microbubble-based approach for cell separation, which markedly improves the viability and health of the T cells while facilitating their application in CAR-T therapies. Dr. Wes Wierson, the CEO of LEAH Labs, commented on this success by highlighting the potential of Akadeum's technology in producing reproducible and efficient cellular therapies. He emphasized that their partnership will ultimately lead to the development of next-generation therapies for both pets and their human companions.
The significance of this success extends beyond veterinary medicine. The advancements made in treating dogs can offer valuable insights into CAR-T treatment for human patients suffering from similar lymphomas. By constructing a solid foundation for tracking engineered T cells in animals, researchers could potentially enhance T cell therapies available for humans battling cancer.
Brandon McNaughton, CEO of Akadeum Life Sciences, expressed pride in the success of the treatment, stating that it demonstrates the versatility and impact of their cell therapy platform in both human and veterinary realms. Akadeum is committed to advancing cell separation technologies to facilitate breakthroughs across a variety of life sciences applications.
With the proven efficacy of CAR-T in dogs, there is considerable excitement about the prospects it brings for future cancer treatments. Continued research will explore the outcomes of such innovative therapies and their potential to revolutionize the treatment landscape for cancers across species. LEAH Labs' unique approach, utilizing a patented gene integration technology called GeneWeld to provide rapid iterations on CAR-T therapies, has set the stage for not only improving treatments for pets but possibly paving the way for human applications as well.
As Akadeum prepares for the publication of detailed study results, the veterinary and medical communities await further updates that could shape the future of cancer care, benefitting both pets and their owners. This collaboration between Akadeum and LEAH Labs represents a significant leap towards improving cancer therapies and may inspire results in clinical applications for human healthcare, especially in the realm of personalized medicine and innovative treatment strategies.
In summary, the first successful canine cancer treatment via human CAR-T cell therapy showcases the potential for veterinary medicine to contribute to major advancements in oncology, all thanks to Akadeum's visionary technology and collaborative efforts in research and development.
Two dogs, named Lou and Sadie, were the first to receive this pioneering treatment. Lou, a 10-year-old Beagle, and Sadie, an 8-year-old Collie/Pyrenees mix, were both diagnosed with advanced stages of a severe form of canine lymphoma, known as metastatic multicentric diffuse large B cell lymphoma. Traditionally, this diagnosis carries a grim prognosis; however, the newly adopted CAR-T cell therapy, utilizing genetically engineered human T cells isolated through Akadeum's technology, has resulted in a stunning turnaround.
After receiving the infusion of the CAR-T cells, both dogs experienced complete clinical remission within a remarkably short period, making history as the first patients ever to undergo such treatment with CAR-T cells in a veterinary setting. Throughout a three-week observational study, consistent measurements illustrated a significant decrease in tumor size across various sites, confirmed by X-ray and ultrasound imaging. Furthermore, the process utilized advanced PET imaging technology that allowed visualization of the CAR T cells in their injected lymph nodes.
This innovative technology employed by Akadeum relies on a microbubble-based approach for cell separation, which markedly improves the viability and health of the T cells while facilitating their application in CAR-T therapies. Dr. Wes Wierson, the CEO of LEAH Labs, commented on this success by highlighting the potential of Akadeum's technology in producing reproducible and efficient cellular therapies. He emphasized that their partnership will ultimately lead to the development of next-generation therapies for both pets and their human companions.
The significance of this success extends beyond veterinary medicine. The advancements made in treating dogs can offer valuable insights into CAR-T treatment for human patients suffering from similar lymphomas. By constructing a solid foundation for tracking engineered T cells in animals, researchers could potentially enhance T cell therapies available for humans battling cancer.
Brandon McNaughton, CEO of Akadeum Life Sciences, expressed pride in the success of the treatment, stating that it demonstrates the versatility and impact of their cell therapy platform in both human and veterinary realms. Akadeum is committed to advancing cell separation technologies to facilitate breakthroughs across a variety of life sciences applications.
With the proven efficacy of CAR-T in dogs, there is considerable excitement about the prospects it brings for future cancer treatments. Continued research will explore the outcomes of such innovative therapies and their potential to revolutionize the treatment landscape for cancers across species. LEAH Labs' unique approach, utilizing a patented gene integration technology called GeneWeld to provide rapid iterations on CAR-T therapies, has set the stage for not only improving treatments for pets but possibly paving the way for human applications as well.
As Akadeum prepares for the publication of detailed study results, the veterinary and medical communities await further updates that could shape the future of cancer care, benefitting both pets and their owners. This collaboration between Akadeum and LEAH Labs represents a significant leap towards improving cancer therapies and may inspire results in clinical applications for human healthcare, especially in the realm of personalized medicine and innovative treatment strategies.
In summary, the first successful canine cancer treatment via human CAR-T cell therapy showcases the potential for veterinary medicine to contribute to major advancements in oncology, all thanks to Akadeum's visionary technology and collaborative efforts in research and development.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.